TP53 and B-cell chronic lymphocytic leukemia: The high risk features of this cohort included treated or untreated CLL patients with 17p13.1 deletion/TP53 mutation, relapsed CLL with 11q22.3 deletion, and /or progression free survival less than 36 months after chemoimmunotherapy.